Modulators of erythropoiesis: Emerging therapies for hemoglobinopathies and disorders of red cell production

Hematology/Oncology Clinics of North America

Volumn 28, Issue 2, 2014, Pages 375-386

  Breda, Laura ^a   Rivella, Stefano ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

ACE 011; ACE 536; Hemoglobinopathies; JAK2; LY 2157299; Steady state; Stress and ineffective erythropoiesis; Transforming growth factor

Indexed keywords

ACTIVIN A; ANTIANEMIC AGENT; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; FOLLITROPIN; GALUNISERTIB; INHIBIN A; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LUSPATERCEPT; SOTATERCEPT; STAT5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; ACE-011; ACTIVIN RECEPTOR 2; HYBRID PROTEIN; RAP-536;

ANEMIA; AUTOPHOSPHORYLATION; BETA THALASSEMIA; BONE METASTASIS; CARCINOGENESIS; CHRONIC STRESS; COMORBIDITY; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; HEMATOPOIESIS; HEMOGLOBINOPATHY; HUMAN; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BETA-THALASSEMIA; DRUG EFFECTS; ERYTHROCYTE; HEMOGLOBINOPATHIES; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; TRENDS;

ACTIVIN RECEPTORS, TYPE II; BETA-THALASSEMIA; ERYTHROCYTES; ERYTHROPOIESIS; HEMOGLOBINOPATHIES; HUMANS; JANUS KINASE 2; MOLECULAR TARGETED THERAPY; RECOMBINANT FUSION PROTEINS;

EID: 84896718827     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.12.001     Document Type: Review

References (82)

1. Chasis J.A. Erythroblastic islands: specialized microenvironmental niches for erythropoiesis. Curr Opin Hematol 2006, 13:137-141.
2. Chasis J.A., Mohandas N. Erythroblastic islands: niches for erythropoiesis. Blood 2008, 112:470-478.
3. Ramos P., Casu C., Gardenghi S., et al. Macrophages support pathological erythropoiesis in polycythemia vera and beta-thalassemia. Nat Med 2013, 19:437-445.
4. Jacobs K., Shoemaker C., Rudersdorf R., et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985, 313:806-810.
5. Lin F.K., Suggs S., Lin C.H., et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985, 82:7580-7584.
6. Bunn H.F. Erythropoietin. Cold Spring Harb Perspect Med 2013, 3:a011619.
7. Tsai S.F., Martin D.I., Zon L.I., et al. Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells. Nature 1989, 339:446-451.
8. D'Andrea A.D., Lodish H.F., Wong G.G. Expression cloning of the murine erythropoietin receptor. Cell 1989, 57:277-285.
9. D'Andrea A., Fasman G., Wong G., et al. Erythropoietin receptor: cloning strategy and structural features. Int J Cell Cloning 1990, 8(Suppl 1):173-180.
10. Witthuhn B.A., Quelle F.W., Silvennoinen O., et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993, 74:227-236.
11. Argetsinger L.S., Campbell G.S., Yang X., et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 1993, 74:237-244.
12. Neubauer H., Cumano A., Muller M., et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998, 93:397-409.
13. Wojchowski D.M., Gregory R.C., Miller C.P., et al. Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999, 253:143-156.
14. Wojchowski D.M., Sathyanarayana P., Dev A. Erythropoietin receptor response circuits. Curr Opin Hematol 2010, 17:169-176.
15. Porpiglia E., Hidalgo D., Koulnis M., et al. Stat5 signaling specifies basal versus stress erythropoietic responses through distinct binary and graded dynamic modalities. PLoS Biol 2012, 10:e1001383.
16. Libani I.V., Guy E.C., Melchiori L., et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. Blood 2008, 112:875-885.
17. Chow A., Huggins M., Ahmed J., et al. CD169(+) macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat Med 2013, 19:429-436.
18. Saharinen P., Takaluoma K., Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000, 20:3387-3395.
19. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
20. James C., Ugo V., Le Couedic J.P., et al. Aunique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
21. Kralovics R., Passamonti F., Buser A.S., et al. Again-of-function mutation of JAK2 in myeloproliferative disorders. NEngl J Med 2005, 352:1779-1790.
22. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
23. Zhao R., Xing S., Li Z., et al. Identification of an acquired JAK2 mutation in polycythemia vera. JBiol Chem 2005, 280:22788-22792.
24. Atallah E., Verstovsek S. Emerging drugs for myelofibrosis. Expert Opin Emerg Drugs 2012, 17:555-570.
25. Hensley B., Geyer H., Mesa R. Polycythemia vera: current pharmacotherapy and future directions. Expert Opin Pharmacother 2013, 14:609-617.
26. Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013, 88:507-516.
27. Ginzburg Y., Rivella S. Beta-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood 2011, 118:4321-4330.
28. Rivella S. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood Rev 2012, 26(Suppl 1):S12-S15.
29. Musallam K.M., Rivella S., Vichinsky E., et al. Non-transfusion-dependent thalassemias. Haematologica 2013, 98:833-844.
30. Rivella S. Ineffective erythropoiesis and thalassemias. Curr Opin Hematol 2009, 16:187-194.
31. Rivella S., Rachmilewitz E. Future alternative therapies for beta-thalassemia. Expert Rev Hematol 2009, 2:685.
32. Melchiori L., Gardenghi S., Rivella S. Beta-thalassemia: HiJAKing ineffective erythropoiesis and iron overload. Adv Hematol 2010, 2010:938640.
33. Gardenghi S., Grady R.W., Rivella S. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in beta-thalassemia. Hematol Oncol Clin North Am 2010, 24:1089-1107.
34. Harrison C.A., Al-Musawi S.L., Walton K.L. Prodomains regulate the synthesis, extracellular localisation and activity of TGF-beta superfamily ligands. Growth Factors 2011, 29:174-186.
35. Akhurst R.J., Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 2012, 11:790-811.
36. Worthington J.J., Klementowicz J.E., Travis M.A. TGFbeta: a sleeping giant awoken by integrins. Trends Biochem Sci 2011, 36:47-54.
37. Tsuchida K., Nakatani M., Hitachi K., et al. Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal 2009, 7:15.
38. Makanji Y., Temple-Smith P.D., Walton K.L., et al. Inhibin B is a more potent suppressor of rat follicle-stimulating hormone release than inhibin a invitro and invivo. Endocrinology 2009, 150:4784-4793.
39. Walton K.L., Makanji Y., Robertson D.M., et al. The synthesis and secretion of inhibins. Vitam Horm 2011, 85:149-184.
40. Walton K.L., Makanji Y., Harrison C.A. New insights into the mechanisms of activin action and inhibition. Mol Cell Endocrinol 2012, 359:2-12.
41. Matzuk M.M., Lu N., Vogel H., et al. Multiple defects and perinatal death in mice deficient in follistatin. Nature 1995, 374:360-363.
42. Fields S.Z., Parshad S., Anne M., et al. Activin receptor antagonists for cancer-related anemia and bone disease. Expert Opin Investig Drugs 2013, 22:87-101.
43. Besa E.C. Myelodysplastic syndromes (refractory anemia). A perspective of the biologic, clinical, and therapeutic issues. Med Clin North Am 1992, 76:599-617.
44. Ineffective erythropoiesis. Lancet 1973, 301:1164-1165.
45. Centis F., Tabellini L., Lucarelli G., et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood 2000, 96:3624-3629.
46. Cappellini M.D. The thalassemias. Goldman's Cecil medicine 2011, 1060-1066. Elsevier, Philadelphia. L. Goldman, A.I. Shafer (Eds.).
47. Steinberg M.H. Sickle cell disease and other hemoglobinopathies. Goldman's Cecil medicine 2011, 1066-1075. Elsevier, Philadelphia. L. Goldman, A.I. Shafer (Eds.).
48. Rivella S. Do not super-excess me!. Blood 2012, 119:5064-5065.
49. Bowman W.D. Abnormal ("ringed") sideroblasts in various hematologic and non-hematologic disorders. Blood 1961, 18:662-671.
50. Tanno T., Miller J.L. Iron loading and overloading due to ineffective erythropoiesis. Adv Hematol 2010, 2010:358283.
51. Wu C.J., Krishnamurti L., Kutok J.L., et al. Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood 2005, 106:3639-3645.
52. Bohlius J., Schmidlin K., Brillant C., et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009, 373:1532-1542.
53. Steensma D.P. Hematopoietic growth factors in myelodysplastic syndromes. Semin Oncol 2011, 38:635-647.
54. Perrien D.S., Akel N.S., Edwards P.K., et al. Inhibin A is an endocrine stimulator of bone mass and strength. Endocrinology 2007, 148:1654-1665.
55. Gaddy-Kurten D., Coker J.K., Abe E., et al. Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology 2002, 143:74-83.
56. Gajos-Michniewicz A., Piastowska A.W., Russell J.A., et al. Follistatin as a potent regulator of bone metabolism. Biomarkers 2010, 15:563-574.
57. Leto G., Incorvaia L., Badalamenti G., et al. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 2006, 23:117-122.
58. Terpos E., Kastritis E., Christoulas D., et al. Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol 2012, 23:2681-2686.
59. Vallet S., Mukherjee S., Vaghela N., et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 2010, 107:5124-5129.
60. Matzuk M.M., Finegold M.J., Su J.G., et al. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 1992, 360:313-319.
61. Cipriano S.C., Chen L., Kumar T.R., et al. Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice. Endocrinology 2000, 141:2319-2327.
62. Takabe K., Wang L., Leal A.M., et al. Adenovirus-mediated overexpression of follistatin enlarges intact liver of adult rats. Hepatology 2003, 38:1107-1115.
63. Maguer-Satta V., Bartholin L., Jeanpierre S., et al. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family. Exp Cell Res 2003, 282:110-120.
64. Maguer-Satta V., Rimokh R. FLRG, member of the follistatin family, a new player in hematopoiesis. Mol Cell Endocrinol 2004, 225:109-118.
65. Johansson B.M., Wiles M.V. Evidence for involvement of activin A and bone morphogenetic protein 4 in mammalian mesoderm and hematopoietic development. Mol Cell Biol 1995, 15:141-151.
66. Li F., Lu S., Vida L., et al. Bone morphogenetic protein 4 induces efficient hematopoietic differentiation of rhesus monkey embryonic stem cells invitro. Blood 2001, 98:335-342.
67. Shiozaki M., Sakai R., Tabuchi M., et al. Invivo treatment with erythroid differentiation factor (EDF/activin A) increases erythroid precursors (CFU-E and BFU-E) in mice. Biochem Biophys Res Commun 1989, 165:1155-1161.
68. Fuchs O., Simakova O., Klener P., et al. Inhibition of Smad5 in human hematopoietic progenitors blocks erythroid differentiation induced by BMP4. Blood Cells Mol Dis 2002, 28:221-233.
69. Perry J.M., Harandi O.F., Paulson R.F. BMP4, SCF, and hypoxia cooperatively regulate the expansion of murine stress erythroid progenitors. Blood 2007, 109:4494-4502.
70. Perry J.M., Harandi O.F., Porayette P., et al. Maintenance of the BMP4-dependent stress erythropoiesis pathway in the murine spleen requires hedgehog signaling. Blood 2009, 113:911-918.
71. Schneyer A.L., Sidis Y., Gulati A., et al. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin. Endocrinology 2008, 149:4589-4595.
72. Maguer-Satta V., Bartholin L., Jeanpierre S., et al. Expression of FLRG, a novel activin A ligand, is regulated by TGF-beta and during hematopoiesis [corrected]. Exp Hematol 2001, 29:301-308.
73. Imamura T., Takase M., Nishihara A., et al. Smad6 inhibits signalling by the TGF-beta superfamily. Nature 1997, 389:622-626.
74. Zhou L., McMahon C., Bhagat T., et al. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res 2011, 71:955-963.
75. Liu T., Feng X.H. Regulation of TGF-beta signalling by protein phosphatases. Biochem J 2010, 430:191-198.
76. Aaron W., Mulivor D.B., Kumar R., et al. RAP-011, a soluble activin receptor type IIa murine IgG-Fc fusion protein, prevents chemotherapy induced anemia. Blood 2009, Available at:. http://https://ash.confex.com/ash/2009/webprogram/Paper23536.html.
77. Chantry A.D., Heath D., Mulivor A.W., et al. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction invivo. JBone Miner Res 2010, 25:2633-2646.
78. Kim K.T., Borgstein N.G., Yang Y., et al. ACE-011, a soluble activin receptor type IIaIgG-Fc fusion protein, increases hemoglobin and hematocrit levels in postmenopausal healthy women. Blood 2008, Available at:. https://ash.confex.com/ash/2008/webprogram/Paper13363.html.
79. Ruckle J., Jacobs M., Kramer W., et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. JBone Miner Res 2009, 24:744-752.
80. Iancu-Rubin C., Mosoyan G., Wang J., et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol 2013, 41:155-166.e17.
81. Rajasekhar NV, Suragani RL, Sako D, etal. RAP-536 promotes terminal erythroid differentiation and reduces anemia in a murine model of myelodysplastic syndromes. In 54th ASH Annual Meeting and Exposition. Atlanta, GA. December 8-11, 2012.
82. Lin Y.W., Slape C., Zhang Z., et al. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood 2005, 106:287-295.